A new biotech is hitting the Boston scene with $50 million from Flagship Pioneering and a goal of preventing patients from ever getting seriously sick in the first place. Etiome has spent the last ...

Flagship Pioneering has a knack for peering into the future. Recently, the $14 billion biotech venture capital firm that launches and runs its own companies has been leveraging that ecosystem to ...

Elaine Chen covers biotech, co-writes The Readout newsletter ... What are the products that will come out of Flagship’s latest startup centered around “preemptive medicine”?

Flagship – which was behind the founding of mRNA specialist Moderna and is run by the biotech’s co-founder, Noubar Afeyan – has been making waves in the biotech sector in the last few years ...

A new Cambridge biotech is creating a roadmap to expand preventive health to a broader range of diseases, treating patients before they become irreversibly ill. Business of Pride Join the Boston ...

a former Pfizer strategy executive who joined Flagship in 2016 as a senior partner and president of Rubius Therapeutics, took the helm of Repertoire. In April 2024, the revamped biotech snagged ...